Profile
Dr Koo Wen Hsin is a Senior Consultant (Division of Medical Oncology) at the National Cancer Centre Singapore (NCCS), as well as the Associate Programme Director for SingHealth Internal Medicine residency and SingHealth Group Director for Education. Dr Koo also holds academic positions in the Duke-NUS Medical School and the Yong Loo Lin School of Medicine at the National University of Singapore. He also set up the Academic Medicine Education Institute (AMEI).
As the chairman for the Medical Oncology Specialist Training Committee for several years, he successfully guided the various institutions in transiting to senior residency in medical oncology. It is also with this same collaborative spirit that Dr Koo helped set up and provided oncologic training to physicians at Tan Tock Seng Hospital, Changi General Hospital and KKH Women’s and Children’s Hospital.
Dr Koo has also initiated many new educational programmes for the upgrading and training for those in the medical profession. He also plays an active role in the education of oncology nurses and lecturers for the Master of Nursing Course at NUS and the Palliative courses at Singapore Hospice Council.
Education
- Executive MBA, Singapore Management University
- MRCP (UK), Membership of the Royal College of Physicians, UK
- MBBS (Singapore), National University of Singapore
View More +
Professional Appointments and Committee Memberships
- Chairperson, Medical Audit Committee, Sengkang General Hospital
- Associate Professor, NUS Yong Loo Lin School of Medicine
- Chairman, Department of General Medicine, Sengkang General Hospital
- Associate Professor, Duke-NUS Medical School
- Co-Group Director, Academic Medicine Education Institute (AM•EI)
View More +
Awards
- National Outstanding Clinician Educator Award, National Medical Excellence Awards 2013
- National Day Award 2018, Public Administration Medal (Bronze)
View More +
Publications
- Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol. 2016 Aug 23;3(1):e000095.
- Ting DS, Lee JC, Loo BK, Baisa K, Koo WH, Cook S, Lim BL. A nationwide, resident-led teaching programme for medical students in Singapore: SingHealth Student Internship Programme Bootcamp. Singapore Med J. 2016 May;57(5):233-7.
- Goh SH, Tan KH, Kamei RK, Koo WH, Cook S. Academic Medicine Education Institute (AM·EI): Transforming the Educational Culture of Health Professionals. Ann Acad Med Singapore. 2015 May;44(5):172-7.
- Farid M, Lee MJ, Chew MH, Ong WS, Sairi AN, Foo KF, Choo SP, Koo WH, Ong S, Koh PK, Quek R. Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. Mol Clin Oncol. 2013 Jan;1(1):190-194.
- Tan WS, Tang CL, Koo WH. Opportunistic screening for colorectal neoplasia in Singapore using faecal immunochemical occult blood test. Singapore Med J 2013;54(4):220-3
- Neo PS, Poon MC, Peh TY, Ong SY, Koo WH, Santoso U, Goh CR, Yee AC. Improvements in end-of-life care with a protocol-based pathway for cancer patients dying in a Singapore hospital. Ann Acad Med Singapore. 2012 Nov;41(11):483-93.
- Farid M, Chowbay B, Chen X, Tan SH, Ramasamy S, Koo WH, Toh HC, Choo SP, Ong SY. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol 2012: 70(1);141-150.
- Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, Koo WH, Choo SP. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol. 2010 Dec;6(4):270-7.
- Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov;10(11):1111-8.
- Cheung YB, Thumboo J, Gao F, Ng GY, Pang G, Koo WH, Sethi VK, Wee J, Goh C. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value in Health 2009 Mar-Apr;12(2):371-6.
View More +
